Calamos Advisors
BEAT

Calamos Advisors’s BioTelemetry, Inc. BEAT Stock Holding History

Calamos Advisors’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,660
Closed -$292K – 805
2019
Q1 		$292K Hold
4,660
– – ﹤0.01% 631
2018
Q4 		$278K Buy
+4,660
New +$280K ﹤0.01% 629

Other funds holding BEAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Calamos Advisors's BEAT Position: Q2 2019 in Review

Calamos Advisors sold out of BioTelemetry, Inc. (BEAT) in Q2 2019, closing a stake of 4,660 shares — an estimated $292K sold.

Calamos Advisors first reported a position in BEAT in Q4 2018 and held it in 2 quarters. The position peaked at $292K in Q1 2019. 251 funds tracked by Wall St. Rank hold BEAT as of Q2 2019.

  • Calamos Advisors reported no remaining BioTelemetry, Inc. position as of Q2 2019 after selling out during the quarter.
  • Calamos Advisors sold 4,660 BioTelemetry, Inc. shares in Q2 2019, an estimated $292K.
  • Calamos Advisors first reported a position in BioTelemetry, Inc. in Q4 2018 and held it in 2 quarters.
  • Calamos Advisors's BioTelemetry, Inc. position peaked at $292K in Q1 2019.
  • 251 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q2 2019.

Based on Calamos Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.